Tumor Necrosis Factor (TNF) Inhibitors: A Clinical Primer
4.8
$ 15.50
In stock
(82)
Product Description
TNF-R1 Cellular Nanovesicles Loaded on the Thermosensitive F-127 Hydrogel Enhance the Repair of Scalded Skin
Melatonin reverses tumor necrosis factor-alpha-induced metabolic disturbance of human nucleus pulposus cells via MTNR1B/Gαi2/YAP signaling
Small tumor necrosis factor receptor biologics inhibit the tumor necrosis factor-p38 signalling axis and inflammation
IJMS, Free Full-Text
Tumor Necrosis Factor: Cell
Tumor Necrosis Factor (TNF) Inhibitors: A Clinical Primer
Tumor Necrosis Factor Receptor 1 - an overview
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review
Tumor Necrosis Factor (TNF) Inhibitors: A Clinical Primer
Targeting Tumor Necrosis Factor Receptor 1 with Selected Aptamers for Anti-Inflammatory Activity
TNF-α induces human neural progenitor cell survival after oxygen–glucose deprivation by activating the NF-κB pathway
Tumor Necrosis Factor Receptor - an overview
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement
Tumor Necrosis Factor (TNF) Inhibitors: A Clinical Primer
/cdn.vox-cdn.com/uploads/chorus_image/image/72565198/1443045799.0.jpg)
